Clinical Drug Experience Knowledgebase

Neoplasms

Adenocarcinoma (Phase 3)

Aged (Phase 2)

Anterior Cruciate Ligament Injuries (Phase 2)

Bile Duct Neoplasms (Phase 2)

Biliary Tract Neoplasms (Phase 3)

Breast Neoplasms (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cetuximab (Phase 2)

Chemoradiotherapy (Phase 3)

Chemoradiotherapy, Adjuvant (Phase 2)

Chemotherapy, Adjuvant (Phase 3)

Cholangiocarcinoma (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Digestive System Neoplasms (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Drug Therapy (Phase 2)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 3)

Esophagogastric Junction (Phase 2)

Gastrectomy (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

General Surgery (Phase 2/Phase 3)

Head and Neck Neoplasms (Phase 3)

Immune System Diseases (Phase 2)

Immunotherapy (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 2)

Maintenance Chemotherapy (Phase 2)

Malaria (Phase 3)

Melanoma (Phase 1/Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoadjuvant Therapy (Phase 4)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neuroendocrine Tumors (Phase 1/Phase 2)

Oropharyngeal Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Oxaliplatin (Phase 2)

Pancreatic Neoplasms (Phase 4)

Peritoneal Neoplasms (Phase 2)

Pharmacological and Toxicological Phenomena (Phase 2)

Progression-Free Survival (Phase 2)

Radiotherapy (Phase 2/Phase 3)

Radiotherapy, Intensity-Modulated (Phase 2)

Rectal Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 4)

Uterine Cervical Neoplasms (Phase 3)